Azithromycin therapy for neutrophilic airways disease: Myth or magic?

Thorax

Volumn 64, Issue 3, 2009, Pages 186-189

  Idris, Saad F ^a   Chilvers, Edwin R ^a   Haworth, Charles ^b   McKeon, Damian ^a,b   Condliffe, Alison M ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANTIMICROBIAL ACTIVITY; APOPTOSIS; CHOLESTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; LUNG CLEARANCE; LUNG DYSPLASIA; LUNG FIBROSIS; NEUTROPHIL; NONHUMAN; NOSE POLYP; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RHINOSINUSITIS; SIGNAL TRANSDUCTION; TINNITUS;

EID: 61649098009     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.103192     Document Type: Editorial

References (34)

1. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003;97:844-50.
2. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
3. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
4. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
5. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902
6. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukln-8 In patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-70.
7. Piacentini GL, Peron DG, Bodini A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007;28:194-8.
8. Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-3.
9. Nalca Y, Jansch L, Bredenbruch F, et al. Quorumsensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PA01: a global approach. Antimicrob Agents Chemother 2006;50:1680-8.
10. Ichimiya T, Takeoka K, Hiramatsu K, et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa In vitro. Chemotherapy 1996;42:186-91.
11. Starner TD, Shrout JD, Parsek MR, et al. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother 2008;52:137-45.
12. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P aeruginosa lung infection In Cftr(-/-) mice. Antimicrob Agents C/iemof/iec2007;51;3B77-87.
13. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment In Pseudomonas endobronchial infection. Am J Respir Crt Care Med 2004;170:1331-9.
14. Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and Induced Inflammation In DeltaF508 cystic fibrosis mice. Respir Res 2006;7:134.
15. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels In cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007;51:975-81.
16. Ivetic T, V, Bosnjak B, Hrvaclc B, et al. AntiInflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration In mice. Eur J Pharmacol 2006;539:131-8.
17. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-Inflammatory cytokines In tracheal aspirate cells from premature Infants. Pediatr Res 2007;62:483-8.
18. Ballard HO, Bernard P, Quails J, et al. Azithromycin protects against hyperoxlc lung injury In neonatal rats. J Investig Med 2007;55:299-305.
19. Ballard HO, Anstead Ml, Shook AL. Azithromycin In the extremely low birth weight Infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007;8:41-50
20. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides Inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007;7:76-82.
21. Yamada T, Fujleda S, Mori S, et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels In nasal lavage. Am J Rhinol 2000;14:143-8.
22. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L75-85.
23. Wilms EB, Touw DJ, Heljerman HG. Pharmacokinetics of azithromycin In plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy In patients with cystic fibrosis. Ther DrugMonit 2006;28:219-25.
24. Miossec-Bartoli C, Pllatre L, Peyron P, et al. The new ketollde HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob Agents Chemother 1999;43:2457- 62.
25. Silvestři M, Oddera S, Eftlmiadl C, et al. Azithromycin Induces In vitro a time-dependent Increase In the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes without damaging phagocytes. J Antimicrob Chemother 1995;36:941-50.
26. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:828-33.
27. Culic O, Erakovlc V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating Inflammatory mediators In healthy human subjects. Eur J Pharmacol 2002;450:277-89.
28. Parnham MJ, Culic O, Erakovlc V, et al. Modulation of neutrophil and Inflammation markers In chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005;517:132- 43.
29. Koch CC, Esteban DJ, ChIn AC, et al. Apoptosis, oxidative metabolism and interleukln-8 production In human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother 2000;46:19-26.
30. Yamasawa H, Oshlkawa K, Ohno S, et al. Macrolides Inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colonystimulating factor release. Am J Respir Cell Mol Biol 2004;30:569-75.
31. Hodge S, Hodge G, Brozyna S, et al. Azithromycin Increases phagocytosis of apoptotlc bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006;28:486-95.
32. Hodge S, Hodge G, Jersmann H, et al. Azithromycin Improves macrophage phagocytic function and expression of mannose receptor In chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:139-48.
33. Seemungal TAR, Wilkinson TMA, Perera W, et al. Long term macrolide therapy decreases exacerbations of COPD. Am J Respir Crit Care Med 2007;175:A764.
34. Abdelghaffar H, Vazlfeh D, Labro MT. Erythromycin Aderlved macrolldes modify the functional activities of human neutrophils by altering the phospholipase Dphosphatldate phosphohydrolase transduction pathway: L-cladinose is Involved both In alterations of neutrophil functions and modulation of this transductlonal pathway. J Immunol 1997;159:3995-4005.